Most peptides in the incretin field trace back to a single gut hormone. Survodutide traces back to two. Known in the lab literature as BI 456906, it is a dual agonist built to switch on both the GLP-1 receptor and the glucagon receptor at once — a design that took more than a decade to move from a licensing contract to late-stage human trials. This is the history of how it got there, and where it still sits today.
What is survodutide (BI 456906)?
Survodutide is an investigational, long-acting peptide engineered as a GLP-1 glucagon dual agonist. Its structure descends from oxyntomodulin, a naturally occurring gut hormone that activates both receptors. GLP-1 signaling is the pathway made famous by drugs like semaglutide; the glucagon arm adds a separate mechanism tied to energy expenditure and liver metabolism. Combining the two in one molecule was the central bet behind the compound. Throughout its development it has carried the code name BI 456906, with “survodutide” adopted as the international nonproprietary name.
The 2011 origin: a Danish peptide meets a German partner
The story starts on 16 June 2011, when Denmark’s Zealand Pharma and Germany’s Boehringer Ingelheim announced a global licence and collaboration agreement covering dual-acting glucagon/GLP-1 receptor agonists for type 2 diabetes and obesity. Zealand contributed the peptide chemistry, including its lead candidate of the era, ZP2929. Boehringer Ingelheim took global development and commercialization rights and funded the program. The deal was reported at up to roughly €41 million in early signature, milestone and research payments — modest by today’s obesity-market standards, and a signal of how early the science still was.
For several years the work stayed in preclinical and early-phase research, refining candidates for balanced activity at both receptors. The molecule that became survodutide, BI 456906, eventually emerged from that effort as the lead the two companies carried forward.
The Phase 2 years: obesity and the liver
In April 2021, Boehringer Ingelheim and Zealand announced the program was advancing into Phase 2 testing in both obesity and NASH (non-alcoholic steatohepatitis, later reclassified as MASH). Two mid-stage readouts followed and gave the compound its clearest data to date.
The obesity dose-finding trial ran across 43 centers in 12 countries. In results published in The Lancet Diabetes & Endocrinology in early 2024, researchers reported that after 46 weeks of once-weekly subcutaneous treatment, mean body-weight change from baseline reached about −14.9% in the highest-dose group versus −2.8% with placebo. Notably, the authors observed no weight plateau by week 46. Gastrointestinal effects were the most common adverse events, consistent with the incretin class.
The second readout targeted the liver. In June 2024, The New England Journal of Medicine published a 48-week Phase 2 trial of survodutide in adults with biopsy-confirmed MASH and fibrosis (NEJMoa2401755), with results also presented at the EASL 2024 congress. Investigators reported that improvement in MASH without worsening of fibrosis occurred in 47%, 62% and 43% of participants across the survodutide dose groups, compared with 14% on placebo. The authors concluded the findings warranted further investigation in Phase 3.
Where survodutide sits in the incretin lineage
Survodutide is best understood next to its cousins. Single-target GLP-1 agonists came first. Tirzepatide, developed by Eli Lilly, pairs GLP-1 with GIP as a dual agonist and reached approval. Retatrutide, also from Lilly, goes a step further as a triple agonist hitting GLP-1, GIP and glucagon receptors, and remains in late-stage study. Survodutide occupies a distinct combination in that family: GLP-1 plus glucagon, without GIP. Each molecule tests a different hypothesis about which receptor mix drives metabolic and liver effects, which is part of why the class is being studied in parallel rather than as a single lineage.
The late-stage chapter — and what remains unproven
Building on the Phase 2 signals, the compound moved into the Phase 3 SYNCHRONIZE program. In April 2026, Boehringer Ingelheim reported topline results from SYNCHRONIZE-1 in obesity, describing weight loss of up to about 16.6% at 76 weeks versus 3.2% with placebo using the trial’s efficacy estimand. Full peer-reviewed data and any regulatory decisions extend beyond those headline figures.
It is worth being precise about maturity: as of this writing, survodutide is an investigational compound. It has strong mid-stage data and reported late-stage topline results, but it is not an approved medicine, and outcomes described in trials should not be read as established or generalized conclusions. Its full safety and efficacy profile is still being characterized through ongoing research.
Research use only. Any survodutide referenced here is supplied strictly as a research compound for laboratory use, not for human or animal use. Every batch is independently third-party lab-tested with a published Certificate of Analysis (COA).